Skip to main content

Table 1 Patients’ baseline characteristics

From: Toxicities of docetaxel: original drug versus generics—a comparative study about 81 cases

  Original drug
(n = 38)
Generic 1
(n = 15)
Generic 2
(n = 17)
Generic 3
(n = 11)
Total
(n = 81)
Age (ans)a 46.2 ± 8.2 48.5 ± 8.7 53 ± 10.7 48.1 ± 9.2 48.3 ± 9.2
Sex
 Male 6 (15.8 %) 2 (13.3 %) 7 (41.2 %) 2 (18.2 %) 17 (21 %)
 Female 32 (84.2 %) 13 (86.7 %) 10 (58.8 %) 9 (81.8 %) 64 (79 %)
Cancer diagnosis
 Early breast 26 (68.4 %) 9 (60 %) 9 (52.9 %) 8 (72.7 %) 52 (64.2 %)
 Metastatic breast 6 (15.8 %) 4 (26.7 %) 1 (5.9 %) 1 (9.1 %) 12 (14.8 %)
 Gastric 2 (5.3 %) 0 2 (11.8 %) 0 4 (4.9 %)
 Head and neck 1 (2.6 %) 2 (13.3 %) 1 (5.9 %) 0 4 (4.9 %)
 Lung 1 (2.6 %) 0 2 (11.8 %) 0 3 (3.7 %)
 Prostate 2 (5.3 %) 0 2 (11.8 %) 1 (9.1 %) 5 (6.2 %)
 Sarcoma 0 (0 %) 0 0 1 (9.1 %) 1 (1.2 %)
Chemotherapy protocol
 T 9 (23.7 %) 4 (26.7 %) 7 (41.2 %) 3 (27.3 %) 23 (28.4 %)
 FEC-T 22 (57.9 %) 7 (46.7 %) 8 (47.1 %) 7 (63.6 %) 44 (54.3 %)
 FEC-TH 4 (10.5 %) 2 (13.3 %) 1 (5.9 %) 1 (9.1 %) 8 (9.9 %)
 TPF 1 (2.6 %) 2 (13.3 %) 1 (5.9 %) 0 4 (4.9 %)
 TH 2 (5.3 %) 0 0 0 2 (2.5 %)
Number of chemotherapy coursesb 3 [3, 5] 3 [2, 3] 3 [3, 4.5] 3 [2, 3] 3 [3, 4]
  1. T taxotere, FEC 5-fluorouracil + epirubicin + cyclophosphamide, TH docetaxel + trastuzumab, TPF docetaxel + cisplatin + 5-fluorouracil
  2. aMean ± standard deviation
  3. bMedian [interquartile range]